FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1443-1444 May 25, 1995 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Not so long ago, therapies that led to a survival advantage in randomized trials were quickly endorsed and adopted. The costs required to achieve the clinical benefit were of only minimal interest to the primary decision makers — physicians seeking the best outcomes for their patients. And in that era there would have been little controversy over whether tissue plasminogen activator (t-PA) is a more effective thrombolytic agent than intravenous streptokinase. Laboratory and clinical studies show that t-PA opens coronary arteries occluded by thrombus more rapidly than streptokinase,¹ and the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded . . . [Full Text of this Article]

References

Related Letters:

Is the Use of t-PA as Compared with Streptokinase Cost Effective?
Rose E. A., Armentano R., Favaloro R. G., Mark D. B.
Extract | Full Text  
N Engl J Med 1995; 333:1009-1010, Oct 12, 1995. Correspondence

This article has been cited by other articles:

• Willerson, J. T. (2003). Myocardial Revascularization with Cardiologic Interventional Devices. Card Surg Adult 2: 561-580 [Full Text]  
• Rose, E. A., Armentano, R., Favaloro, R. G., Mark, D. B. (1995). Is the Use of t-PA as Compared with Streptokinase Cost Effective?. NEJM 333: 1009-1010 [Full Text]